CHESTER, NJ (May 17, 2004) – Adams Respiratory Therapeutics, a maker of specialty pharmaceuticals for respiratory care, announced last week the relocation of its corporate headquarters from Fort Worth, Texas, to Chester, New Jersey.
A new 14,000 square-foot facility will house the company’s executive offices, including sales, marketing, finance, business development and legal.
Referring to the Chester-area as “the hub of pharmaceutical development and marketing,” Michael J. Valentino, president and chief executive officer, termed the move a “strategic step” in the company’s effort to grow its respiratory product portfolio. Meanwhile, H. F. (Harry) Oberkfell, age 57, was appointed to the Adams board of directors, increasing the board size to eight and Robert Casale, age 45, was appointed to the new position of vice president, OTC marketing and business development.
Oberkfell was an officer with Warner-Lambert for more than 30 years, serving as chief knowledge officer, president of the company’s Latin America/Asia sector and president of the company’s North American Parke-Davis subsidiary. In the former two positions, Oberkfell led the launches of Lipitor and Rezulin in Latin America and Asia, and initiated a company-wide knowledge resource initiative.
Casale, prior to joining Adams, served as a vice president of marketing for both Warner-Lambert and Pfizer Consumer Healthcare. In his new position, Casale will be responsible for OTC marketing and the external sourcing of new business opportunities, the company said.
Adams Respiratory Therapeutics develops, markets and sells prescription and non-prescription pharmaceuticals for the treatment of respiratory disorders and diseases.